Efficacy and Tolerability of Weekly Docetaxel, Cisplatin, and 5-Fluorouracil for Locally Advanced or Metastatic Gastric Cancer Patients with ECOG Performance Scores of 1 and 2

Turkeli, Mehmet; Aldemir, Mehmet Naci; Cayir, Kerim; Simsek, Melih; Bilici, Mehmet; Tekin, Salim Basol; Yildirim, Nilgun; Bilen, Nurhan; Makas, Ibrahim

추천

검색

자료유형: 학술저널

저자정보: Turkeli, Mehmet (Department of Medical Oncology, Faculty of Medicine, Ataturk University Erzurum) Aldemir, Mehmet Naci (Department of Medical Oncology, Faculty of Medicine, Ataturk University Erzurum) Cayir, Kerim (Department of Medical Oncology, Faculty of Medicine, Ataturk University Erzurum) Simsek, Melih (Department of Medical Oncology, Faculty of Medicine, Ataturk University Erzurum) Bilici, Mehmet (Department of Medical Oncology, Faculty of Medicine, Ataturk University Erzurum) Tekin, Salim Basol (Department of Medical Oncology, Faculty of Medicine, Ataturk University Erzurum) Yildirim, Nilgun (Department of Medical Oncology, Faculty of Medicine, Ataturk University Erzurum) Bilen, Nurhan (Department of Internal Medicine, Faculty of Medicine, Ataturk University Erzurum) Makas, Ibrahim (Department of Internal Medicine, Faculty of Medicine, Ataturk University Erzurum)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제16권 제3호

발행연도: 2015.1

수록면: 985 - 989 (5page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: Docetaxel, cisplatin, 5-fluorouracil (DCF) given every three weeks is an effective, but palliative regimen and significantly toxic especially in patients who have a low performance score. Here, we aimed to evaluate the efficacy and tolerability of a weekly formulation of DCF in locally advanced and metastatic gastric cancer patients. Materials and Methods: 64 gastric cancer patients (13 locally advanced and 51 metastatic) whose ECOG (Eastern Cooperative Oncology Group) performance status (PS) was 1-2 and who were treated with at least two cycles of weekly DCF protocol as first-line treatment were included retrospectively. The weekly DCF protocol included $25mg/m^2$ docetaxel, $25mg/m^2$ cisplatin, and 24 hours infusion of $750mg/m^2$ 5-fluorouracil, repeated every week. Disease and patient characteristics, prognostic factors, treatment response, grade 3-4 toxicity related to treatment, progression free survival (PFS) and overall survival (OS) were evaluated. Results: Of the patients, 41 were male and 23 were female; the median age was 63 (29-82) years. Forty-one patients were ECOG-1 and 23 were ECOG-2. Of the total, 81.2% received at least three cycles of chemotherapy. Partial response was observed in 28.1% and stabilization in 29.7%. Overall, the disease was controlled in 57.8% whereas progression was noted in 42.2%. The median time to progression was 4 months (95%CI, 2.8-5.2 months) and median overall survival was 12 months (95%CI, 9.2-14.8 months). The evaluation of patients for grade 3-4 toxicity revealed that 10.9% had anemia, 7.8% had thrombocytopenia and 10.9% had neutropenia. Non-hematologic toxicity included renal toxicity (7.8%) and thrombosis (1.6%). Conclusions: In patients with locally advanced or metastatic gastric cancer who were not candidates for DCF administered every-3-weeks, a weekly formulation of DCF demonstrated modest activity with minimal hematologic toxicity, suggesting that weekly DCF is a reasonable treatment option for such patients.

#Gastric cancer #locally advanced or metastatic cases #docetaxel #cisplatin #5-fluorouracil #schedule

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!